In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Plus Therapeutics Inc (NASDAQ: PSTV) was $0.35 for the day, up 7.00% from the previous closing price of $0.33. In other words, the price has increased by $7.00 from its previous closing price. On the day, 3.78 million shares were traded. PSTV stock price reached its highest trading level at $0.3722 during the session, while it also had its lowest trading level at $0.3402.
Ratios:
Our analysis of PSTV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 0.99.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, D. Boral Capital on March 17, 2025, initiated with a Buy rating and assigned the stock a target price of $9.
On January 25, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $8.
On October 16, 2020, Maxim Group started tracking the stock assigning a Buy rating and target price of $6.Maxim Group initiated its Buy rating on October 16, 2020, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’25 when Petersen Greg bought 36,666 shares for $0.55 per share.
Hawkins Richard J bought 4,000 shares of PSTV for $5,996 on Sep 13 ’24. The Director now owns 15,188 shares after completing the transaction at $1.50 per share. On Sep 12 ’24, another insider, Hawkins Richard J, who serves as the Director of the company, bought 6,285 shares for $1.35 each. As a result, the insider paid 8,512 and bolstered with 11,188 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTV now has a Market Capitalization of 11395366 and an Enterprise Value of -3906030. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19. Its current Enterprise Value per Revenue stands at -0.75 whereas that against EBITDA is 0.275.
Stock Price History:
The Beta on a monthly basis for PSTV is 0.63, which has changed by -0.8387097 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, PSTV has reached a high of $2.55, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -42.86%, while the 200-Day Moving Average is calculated to be -68.18%.
Shares Statistics:
PSTV traded an average of 14.77M shares per day over the past three months and 21885380 shares per day over the past ten days. A total of 32.72M shares are outstanding, with a floating share count of 29.81M. Insiders hold about 8.87% of the company’s shares, while institutions hold 4.89% stake in the company. Shares short for PSTV as of 1747267200 were 3489479 with a Short Ratio of 0.24, compared to 1744675200 on 1128044. Therefore, it implies a Short% of Shares Outstanding of 3489479 and a Short% of Float of 20.639999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Plus Therapeutics Inc (PSTV) in the stock market.The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.08 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$0.34 and -$1.54 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is -$0.76, with 3.0 analysts recommending between -$0.53 and -$1.14.
